Product Profiles: Alzheimer's Disease

Published by: Datamonitor

Published: Oct. 1, 2012 - 114 Pages

Table of Contents

Overview
Catalyst
Summary

Executive Summary
Datamonitor key findings

Product Overview
Product overview

Marketed Product Profiles
Aricept (donepezil; Eisai/Pfizer)
Exelon (rivastigmine; Novartis)
Razadyne (galantamine; Johnson & Johnson/Shire)
Namenda (memantine; Forest/Merz/Lundbeck)

Pipeline Product Profiles
Solanezumab (Eli Lilly)
Gammagard (intravenous immunoglobulin; Baxter)
SB-742457 (GlaxoSmithKline)
Lu AE58054 (Lundbeck)
EVP-6124 (EnVivo Pharmaceuticals/Mitsubishi Tanabe)
7Bapineuzumab (Johnson & Johnson/Pfizer)
Other key disease-modifying drugs in development for Alzheimer’s disease
Other key symptomatic drugs in development for Alzheimer’s disease

Bibliography
Journal papers
Websites
Datamonitor content

Appendix
Physician research methodology
Datamonitor drug assessment scorecard
Contributing experts
Conferences attended
Report methodology

Abstract

The beta-amyloid hypothesis has so far failed to deliver a viable candidate, contributing to an absence of new market entrants over the past decade. However, given the weight of candidates with disease-modifying potential in the pipeline, new drugs are expected to emerge that will satisfy one of the biggest unmet needs in the industry – a treatment that slows Alzheimer’s disease neurodegeneration.

Datamonitor’s physician survey reveals that Aricept finds widespread use across all lines of therapy and severities, from mild cognitive impairment to severe Alzheimer’s disease. However, Eisai faces a steep decline in revenues as generic donepezil take hold in the US, marketed competition heightens in Japan, and European patents near expiry.

Bapineuzumab and solanezumab have the potential to revolutionize Alzheimer’s disease treatment and become future market leaders. However, each program carries a caveat. J&J/Pfizer are relying on post-hoc analyses of bapineuzumab in a subpopulation while Lilly is betting on solanezumab’s Phase II biomarker effect translating into tangible benefits.

A precedent already exists for neurotransmitter mechanisms, ensuring a higher likelihood of navigating through clinical trials. Late-stage symptomatic drugs include Eisai’s Aricept patch and GSK’s 5-HT6 receptor agonist SB-742457, although the potential rewards on offer for these candidates are lower than for the immunotherapies.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.